Related Experiment Videos
Percutaneous myocardial laser revascularization in patients with refractory angina pectoris
Timothy J Gray1, Sharon M Burns, Sarah C Clarke
1Papworth Hospital, Cambridge, United Kingdom. tim_gray@hotmail.com
Insights
Percutaneous myocardial laser revascularization (PMLR) is a safe and effective treatment for severe angina. This procedure improved exercise capacity and quality of life in patients unsuitable for traditional revascularization.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Regenerative Medicine
Background:
- Stable angina pectoris (class III or IV) poses significant challenges for patients unsuitable for conventional revascularization.
- Assessing novel therapeutic approaches is crucial for improving outcomes in refractory ischemic heart disease.
Purpose of the Study:
- To evaluate the safety and efficacy of percutaneous myocardial laser revascularization (PMLR) in patients with severe stable angina.
- To compare PMLR combined with optimal medical therapy against optimal medical therapy alone.
Main Methods:
- A randomized controlled trial involving 73 patients with stable angina (class III-IV).
- Patients were randomized to either optimal medical therapy alone (n=37) or PMLR plus optimal medical therapy (n=36).
- Follow-up assessments included exercise time, angina scores, ejection fraction, quality of life, and hospitalizations at 3, 6, and 12 months.
Main Results:
- PMLR was successfully performed in all 36 patients with no periprocedure deaths; two patients experienced complications (ventricular tachycardia, cardiac tamponade).
- At 12 months, exercise time significantly improved in the PMLR group (+109 seconds) compared to the control group (-62 seconds) (p <0.01).
- PMLR treatment led to a 2-class improvement in angina scores for 36% of patients, versus 0% in the control group (p <0.01), alongside enhanced quality of life.
Conclusions:
- Percutaneous myocardial laser revascularization (PMLR) is a relatively safe interventional procedure.
- PMLR offers significant symptomatic relief for angina patients.
- The procedure enhances exercise capacity and improves the quality of life for patients with refractory angina.
Abstract:
This study aimed to determine the safety and efficacy of percutaneous myocardial laser revascularization (PMLR). Seventy-three patients with stable angina pectoris (class III or IV) who were unsuitable for conventional revascularization and had evidence of reversible ischemia by thallium-201 scintigraphy, ejection fraction of > or =25%, and myocardial wall thickness > or =8 mm were randomized to optimal medical therapy alone (n = 37) or PMLR with optimal medical therapy (n = 36). Patients were followed up at 3, 6, and 12 months. The primary end point was exercise time. Secondary end points included angina scores, left ventricular ejection fraction, quality of life, changes in medical therapy, and hospitalizations. All 36 patients randomized to PMLR underwent the procedure successfully with no periprocedure deaths. One patient developed sustained ventricular tachycardia that required electrical cardioversion, and 1 patient developed cardiac tamponade that required surgical drainage. At 12 months, exercise times improved by 109 seconds in the PMLR group but decreased by 62 seconds in the control group (p <0.01). Angina scores improved by 2 classes in 36% of PMLR-treated patients at 12 months compared with 0% of the control patients (p <0.01). We conclude that PMLR is a relatively safe procedure that provides patients with symptomatic angina relief and improvement in exercise capacity and quality of life.